Castellani: Health Law's Cost-Sharing Could Limit Patient Access To Prescription Drugs

Enrollees in some of the health law's most popular plans will face high cost-sharing requirements that the pharmaceutical industry says could keep patients from getting the drugs they need.
Published Online: May 08, 2014
Enrollees in some of the health law’s most popular plans will face high cost-sharing requirements that the pharmaceutical industry says could keep patients from getting the drugs they need.

Most silver plans in the online marketplaces, or exchanges, require patients to pay for prescription drugs as part of the plan’s deductible, while nearly all bronze plans do, according to a report from Breakaway Health prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA), the drug industry’s trade group.

Silver plans that combine prescription and medical costs into one deductible — the out-of-pocket costs patients pay before coverage begins –  have average deductibles of $2,275, and similar bronze plans have an average of $4,986, according to the report. The average amount for plans that have separate prescription drug deductibles is $470 for a silver plan and $956 for a bronze one.

Read the full story here: http://bit.ly/1jjNSEP

Source: Kaiser Health News



Feature
Recommended Articles
The study found that the geriatric population in the United States receives prescriptions for mental health drugs at more than twice the rate that younger adults do, but they present a lower rate of seeking psychiatric care.
Congressman Frank Pallone, Jr (D-NJ), explains the purpose of the National Institutes of Health Innovation Fund, which allows the organization to find cures for diseases that don’t have 1 yet.
A study published in JAMA Oncology presents a new tool that can predict disease recurrence in oropharyngeal cancer patients.
Proposed mergers of Aetna and Humana, and Anthem and Cigna, raise questions of whether consumers will continue to see competition in health insurance markets.
Earnings calls over the past 2 days for Express Scripts and Sanofi offered starkly different views of pricing for the first PCSK9 inhibitor to reach the US market.